ConductScience.org, home

Paper301897

Inflammatory cells in solid murine neoplasms. IV. Cytolytic T lymphocytes isolated from regressing or progressing Moloney sarcomas.

Gillespie GY and 3 others. J Immunol, 1977. Cited by 57 papers, by iCite.

Cite this record

ConductScience Library. Inflammatory cells in solid murine neoplasms. IV. Cytolytic T lymphocytes isolated from regressing or progressing Moloney sarcomas. Papers, record 301897. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/301897

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Inflammatory cells in solid murine neoplasms. IV. Cytolytic T lymphocytes isolated from regressing or progressing Moloney sarcomas.
PubMed
Journal
J Immunol
PubMed
Year
1977
PubMed
Publication types
Journal Article, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
57
iCite
Relative citation ratio, by iCite
1.54
iCite
Revised in PubMed
2021-12-03
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Gillespie GYG Y
2Hansen CBC B
3Hoskins RGR G
4Russell SWS W

Source PubMed

Download CSV of authors

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Sarcoma, ExperimentalMajor topic
T-LymphocytesMajor topic
Animals
Cytotoxicity Tests, Immunologic
Immunosuppression Therapy
Male
Mice
Mice, Inbred BALB C
Moloney murine leukemia virus
Tumor Virus Infections

Source PubMed

Download CSV of topics

Cited by17

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 57 citations.

PMIDTitleJournalYearIn PapersSource
15678154Enhanced inhibition of syngeneic murine tumors by combinatorial therapy with genetically engineered HSV-1 expressing CCL2 and IL-12.Cancer Gene Ther2005https://conductscience.org/library/papers/15678154PubMed
8270874Interleukin 7 promotes long-term in vitro growth of antitumor cytotoxic T lymphocytes with immunotherapeutic efficacy in vivo.J Exp Med1994https://conductscience.org/library/papers/8270874PubMed
7053211In vitro demonstration of in situ autologous tumour-cell cytotoxicity in MSV-induced tumours in A/SN mice.Br J Cancer1981https://conductscience.org/library/papers/7053211PubMed
6973602Quantitation and clonal isolation of cytolytic T lymphocyte precursors selectively infiltrating murine sarcoma virus-induced tumors.J Exp Med1981https://conductscience.org/library/papers/6973602PubMed
6201854Membranes from T and B lymphocytes have different patterns of tyrosine phosphorylation.Proc Natl Acad Sci U S A1984https://conductscience.org/library/papers/6201854PubMed
6159445
Antigenic specificity of the cytolytic T lymphocyte response to murine sarcoma virus-induced tumors. III. Characterization of cytolytic T lymphocyte clones specific for Moloney leukemia virus-associated cell surface antigens.
J Exp Med1980https://conductscience.org/library/papers/6159445PubMed
3876271
Effector mechanisms of syngeneic anti-tumour responses in mice. I. Establishment and characterization of an exogenous IL-2-independent cytotoxic T-lymphocyte line specific for radiation-induced leukaemia RL male 1.
Immunology1985https://conductscience.org/library/papers/3876271PubMed
2936448Immune surveillance and natural resistance: an evaluation.Cancer Immunol Immunother1986https://conductscience.org/library/papers/2936448PubMed
2502309Augmented induction of antitumor cells in vivo by cyclophosphamide fails to benefit antitumor resistance of the host.Cancer Immunol Immunother1989https://conductscience.org/library/papers/2502309PubMed
2302723Emergence of a dominant cytotoxic T lymphocyte antitumor effector from tumor-infiltrating cells in the anterior chamber of the eye.Cancer Immunol Immunother1990https://conductscience.org/library/papers/2302723PubMed
2289212Mechanisms of tumour rejection in the murine DBA/2-SL2 concomitant immunity system.Cancer Immunol Immunother1990https://conductscience.org/library/papers/2289212PubMed
925611Functional characterization of a stable, noncytolytic stage of macrophage activation in tumors.J Exp Med1977https://conductscience.org/library/papers/925611PubMed
887150Macrophages isolated from regressing Moloney sarcomas are more cytotoxic than those recovered from progressing sarcomas.Nature1977https://conductscience.org/library/papers/887150PubMed
444404Effects of carrageenan, PVP and tumour-bearer serum on immunity induced by excision or mitomycin C-treated tumour cells in mice.Br J Cancer1979https://conductscience.org/library/papers/444404PubMed
375965Systemic and in-situ natural killer activity in tumour-bearing rats.Br J Cancer1979https://conductscience.org/library/papers/375965PubMed
221614Tumors induced by murine sarcoma virus contain precursor cells capable of generating tumor-specific cytolytic T lymphocytes.J Exp Med1979https://conductscience.org/library/papers/221614PubMed
81673Resurgence of killing and in vivo protection mediated by lymphocytes cultured from lymph nodes draining Moloney sarcomas.Br J Cancer1978https://conductscience.org/library/papers/81673PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/301897

GET https://conductscience.org/api/papers/v1/301897/authors